Sonova Holding AG (SWX:SOON)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 13.63B -5.2% |
| Revenue (ttm) | 3.61B -4.8% |
| Net Income | 430.60M -22.1% |
| EPS | 7.22 -21.9% |
| Shares Out | 59.40M |
| PE Ratio | 25.46 |
| Forward PE | 21.45 |
| Dividend | 4.70 (1.99%) |
| Ex-Dividend Date | Jun 19, 2026 |
| Volume | 85,897 |
| Open | 230.20 |
| Previous Close | 229.40 |
| Day's Range | 226.20 - 231.20 |
| 52-Week Range | 163.00 - 248.00 |
| Beta | 1.11 |
| Analysts | Hold |
| Price Target | 230.95 (+2.1%) |
| Earnings Date | Nov 12, 2026 |
About Sonova Holding AG
Sonova Holding AG manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through Hearing Instruments, Cochlear Implants, and Lifestyle-Aligned segments. The Hearing Instruments segment engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitr... [Read more]
Financial Performance
In fiscal year 2026, Sonova Holding AG's revenue was 3.61 billion, a decrease of -0.19% compared to the previous year's 3.61 billion. Earnings were 430.60 million, a decrease of -20.33%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for SOON stock is "Hold." The 12-month stock price target is CHF 230.95, which is an increase of 2.10% from the latest price.
News
Sonova price target raised to CHF 245 from CHF 205 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Sonova (SONVY) to CHF 245 from CHF 205 and keeps an Equal Weight rating on the shares.
SONVF Looks 1.9% Undervalued on GF Value⢠Amid Solid Dividend Sustainability
SONVF Looks 1.9% Undervalued on GF Value⢠Amid Solid Dividend Sustainability
Sonova unveils new AI-powered hearing-aid platform to support growth targets
Sonova launched its third hearing-aid platform utilising real-time AI on Monday, its latest effort to strengthen its position in a market that relies on rapid technology upgrades to shorten replacem...
Sonova price target raised to CHF 205 from CHF 169 at Citi
Citi raised the firm’s price target on Sonova (SONVY) to CHF 205 from CHF 169 and keeps a Sell rating on the shares.
Sonova upgraded to Buy from Neutral at UBS
UBS upgraded Sonova (SONVY) to Buy from Neutral with a price target of CHF 242, up from CHF 206. The shares are trading at their near-largest discount to Demant in…
Sonova upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Sonova (SONVY) to Equal Weight from Underweight with a price target of CHF 205, up from CHF 172. The firm says signs of a growth inflection coupled…
Sonova price target raised to CHF 189 from CHF 163 at JPMorgan
JPMorgan analyst David Adlington raised the firm’s price target on Sonova (SONVY) to CHF 189 from CHF 163 and keeps a Neutral rating on the shares.
Sonova Holding AG Transcript: H2 25/26
Delivered strong sales and profit growth, driven by innovation and market share gains in hearing instruments and retail, while cochlear implants faced headwinds. Outlook for 2026-2027 is positive, with continued above-market growth and margin expansion expected.
Sonova Holding AG Earnings release: H2 2026
Sonova Holding AG released its H2 2026 earnings on May 18, 2026, summarizing the period's financial results.
Sonova Holding AG Annual report: H2 2026
Sonova Holding AG has published its H2 2026 annual report on May 18, 2026.
Sonova Holding AG Slides: H2 2026
Sonova Holding AG has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 18, 2026.
Sonova price target lowered to CHF 169 from CHF 210 at Citi
Citi lowered the firm’s price target on Sonova (SONVY) to CHF 169 from CHF 210 and keeps a Sell rating on the shares.
Sonova price target lowered to CHF 172 from CHF 184 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Sonova (SONVY) to CHF 172 from CHF 184 and keeps an Underweight rating on the shares.
Sonova upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Sonova (SONVY) to Neutral from Underweight with a price target of CHF 163, up from CHF 158. The firm sees the end of negative estimate revisions for Sonova.
Sonova price target lowered to CHF 188 from CHF 237 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Sonova (SONVY) to CHF 188 from CHF 237 and keeps a Hold rating on the shares. Published first on…
Sonova price target lowered to CHF 158 from CHF 176 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Sonova (SONVY) to CHF 158 from CHF 176 and keeps an Underweight rating on the shares.
Sonova Holding AG Transcript: Investor update
A refreshed strategy aims for CHF 6 billion revenue by FY 2031, focusing on hearing care, innovation, and operational excellence. Growth will be driven by market share gains, Asia expansion, and disciplined M&A, with midterm targets of 5%-10% sales CAGR and 7%-12% core EBIT CAGR.
Sonova Holding AG Press release: Investor update
Sonova Holding AG issued a press release on March 23, 2026, disclosing material business information to investors.
Sonova Holding AG Slides: Investor update
Sonova Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Sonova downgraded to Underperform from Hold at Jefferies
Jefferies downgraded Sonova (SONVY) to Underperform from Hold with a price target of CHF 155, down from CHF 215. The stock’s valuation “remains rich” given the company’s slowing growth prospects,…
Sonova upgraded to Outperform from Underperform at BNP Paribas
BNP Paribas upgraded Sonova (SONVY) to Outperform from Underperform with a CHF 230 price target
Sonova expects FY revenue at lower end of target range, CEO says in interview
Sonova's full year revenue will come at the lower end of its 2025/2026 forecast range for growth of 5% to 9%, hearing-aid maker CEO Eric Bernard said in an interview published on Friday.
Sonova initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Sonova (SONVY) with an Outperform rating and CHF 250 price target The firm sees the company’s “market leadership positioning and technological differentiation” drivin...
Sonova price target lowered to CHF 176 from CHF 195 at JPMorgan
JPMorgan lowered the firm’s price target on Sonova (SONVY) to CHF 176 from CHF 195 and keeps an Underweight rating on the shares.
Sonova Holding AG Transcript: H1 25/26
Sales grew 4.9% in local currencies, with strong gains in hearing instruments and audiological care, offsetting weakness in consumer hearing and cochlear implants. Guidance for 5-9% sales growth and 14-18% EBITDA growth is reiterated, supported by new product launches and operational improvements.